Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis by Amponsah, Emmanuel K. et al.
CASE REPORT Open Access
Adverse reaction to Coartem (artemether/
lumefantrine) resulting in oculogyric crisis
Emmanuel Kofi Amponsah1† , Buyanbileg Sodnom-Ish2† , Aaron Sowah Anyetei-Anum1 ,
Paul Frimpong1 and Soung Min Kim1,2*
Abstract
Background: Artemether/lumefantrine (AL), sold under the brand name Coartem, is the most common artemisinin-
based combination therapy for the treatment of malaria. Drug-induced oculogyric crisis is a neurological disorder
characterized by frequent upward deviations of the eye. In the literature, no cases of Coartem-induced oculogyric
crisis have been reported in Ghana.
Case presentation: A 19-year-old male patient, who presented fever measuring 37.9 °C, general body pains, and
weakness was prescribed with antimalarial therapy artemether/lumefantrine, Coartem®, from a local pharmacy. Just
after initiation of treatment, the patient complained of double vision, involuntary upward eye deviation, and
inability to close both eyes. The patient was diagnosed with Coartem-induced oculogyric crisis and was treated
with the cessation of the causing agent and intramuscular injection of promethazine hydrochloride.
Conclusions: When a patient exhibits a neurological disorder, such as oculogyric crisis, with normal conscious state
and normal vital signs, special attention should be given to obtaining a history of recently administered
medications. Clinicians should recognize adverse reactions to drugs based on a thorough patient history and
examination. The goal of this report was to present Coartem-induced oculogyric crisis.
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Background
Artemether/lumefantrine (AL), sold under the brand
name Coartem, is the most common artemisinin-based
combination therapy recommended by the World
Health Organization. Since Plasmodium falciparum be-
came resistant to chloroquine, AL has been used to treat
malaria. It is not typically used to prevent malaria and is
administered orally. Common side effects include muscle
and joint pain, fever, loss of appetite, and headache. One
serious side effect is prolongation of the QT interval.
While not well studied, the use of AL in pregnancy ap-
pears safe [1]. The dosage of AL does not need to be
changed in patients with mild or moderate kidney or
liver problems. AL is on the World Health Organiza-
tion’s Model List of Essential Medicines [2] and is not
available as a generic medication [3].
Case presentation
A 19-year-old male patient reported to the Oral & Max-
illofacial Department of Brong Ahafo Regional Hospital
in Sunyani, Ghana, with involuntary, spontaneous, con-
jugated, and rhythmic upward eye deviation and inability
to close both eyes. Two days prior to presentation at our
facility, he visited a pharmacy with complaints of fever
measuring 37.9 °C, general body pains, and weakness. A
rapid diagnostic test (RDT) conducted at the pharmacy
was positive for Plasmodium falciparum. Therefore, the
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patient received antimalarial therapy artemether/lume-
fantrine, Coartem® (Novartis Pharma AG, Basel,
Switzerland), at a dose of 80/480 mg and to be taken
after 8 h on day one and twice daily thereafter for 2
days.
Just after initiation of treatment, the patient com-
plained of double vision, involuntary upward eye devi-
ation, and inability to close both eyes (Fig. 1a). The
patient did not have any significant medical history. On
physical examination, no signs of dyskinesia with abnor-
mal, uncontrollable, involuntary movements were found.
On neurological examination, the patient was fully alert
and cooperative. Both eyes exhibited conjugate upward
deviation, and the patient was unable to fully close both
eyes (oculogyric crisis). The patient exhibited difficulty
in bringing his eyes back to the primary position and
could not sustain the position; the eyes resumed the up-
ward position within seconds.
Upon the examination of the eyes, the pupils were iso-
coric and reactive to light. Ocular motility and visual
acuity could not be evaluated due to the crisis. Based on
the above-mentioned findings, the patient was diagnosed
with Coartem-induced oculogyric crisis. AL drug treat-
ment was immediately stopped, and 25mg/ml pro-
methazine hydrochloride, Phenergan® (Sanofi, Paris,
France), was administered through intramuscular (IM)
route. The symptoms of oculogyric crisis significantly
improved 1 h after the IM injection. The patient was dis-
charged home on the same day with oral cetirizine (Dex-
cel-Pharma Ltd. Daventry, UK) 10mg daily for 5 days.
He attended a follow-up visit 1 week later, and all symp-
toms had completely disappeared (Fig. 1b).
Discussion
Acute dystonic reactions (ADRs) occur commonly due
to drug use in the form of extrapyramidal adverse reac-
tions particularly involuntary strong contraction of the
face, neck, and back muscles. ADRs can also be a side ef-
fect of other medications, such as antiemetic, anti-
psychotic, antidepressant, antiepileptic, and antimalarial
medications, which produce ADRs due to dopaminergic-
cholinergic imbalance in the basal ganglia [3]. ADRs are
characterized by involuntary contractions in the region
of face, trunk, extremities, pelvis, etc [3, 4]. AL, the
mainstay antimalarial drug, may cause ADRs in patients
at any age, even at therapeutic dosages. The incidence of
Coartem-induced oculogyric crisis has not been reported
in the literature, whereas other antimalarial drugs such
as artesunate/amodiaquine were reported to cause ADRs
in children [3].
AL is thought to be highly effective in treating uncom-
plicated malaria in children and the frequency of associ-
ated side effects is not higher that other available
artemisinin-based combination therapies [5]. Ghana is
an endemic for malaria, where in 2013, 44% of all out-
patient clinic visits and 22.3% of all under-five death
were associated with malaria [6]. Artemisinin is highly
effective in clearing the biomass of Plasmodium within
short time and prevents the maturation of the gameto-
cytes by its partner drug lumefantrine. Lumefantrine is
an aryl amino-alcohol in the same general group as mef-
loquine and halofantrine, offering the maximum dual
performance of AL (Fig. 2) [7]. Therefore, the aim of this
case report is bring to fore the association of AL as a
cause of drug-induced oculogyric crisis.
Fig. 1 Oculogyric crisis in a patient who exhibited paroxysmal, conjugate, tonic, ocular deviations caused by sustained contractions of the ocular
muscles (a). The patient without symptoms following treatment (b)
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Oculogyric crisis is defined as rare nonlife-threatening
neurological manifestation that causes spasmodic move-
ments of the eyeballs into a fixed position that may last
from seconds to hours [3, 8]. The spasms may be
followed by emotional lability, such as restlessness, com-
pulsive thinking, anxiety, and sensations of increased
brightness or visual distortions [6]. Although oculogyric
crisis is mostly drug-induced, it can be seen in hereditary
and sporadic movement disorders and disorders related
to focal brain lesions. Oculogyric crisis must be excluded
from versive seizures, eye movement tics, paroxysmal
tonic upgaze syndrome, and retinal disease. Versive sei-
zures are phenomenologically similar to oculogyric cri-
sis, yet they are fundamentally different [3, 9]. Wyllie
et al. reported that versive seizures can mimic oculogyric
crisis, but they are associated with an alteration of con-
sciousness and should be excluded with an electro-
encephalogram [9]. Paroxysmal tonic upward gaze is
characterized by episodes of sustained conjugate upward
deviation of the eyes and can be differentiated from ocu-
logyric crisis by the presence of neck flexion and con-
comitant episodic ataxia [10].
Considering the important key points including the
medication history and the clinical findings of the pa-
tient, a diagnosis of AL (Coartem)-induced oculogyric
crisis was made. When a patient exhibits the symptoms
of a neurological disorder, such as oculogyric crisis, with
conscious state and normal vital signs, special attention
should be given to recently administered medications.
The management of drug-induced oculogyric crisis in-
cludes discontinuation or, if not possible, reducing the
dose of the opposing agent. The mainstay treatment for
oculogyric crisis is anticholinergics [6]. In our case, the
patient’s symptoms improved within one hour after IM
injection of promethazine hydrochloride.
Conclusions
A literature search demonstrated no published articles
on Coartem-induced oculogyric crisis in Ghana, where
malaria is endemic. When a patient exhibits a neuro-
logical disorder, such as oculogyric crisis, with normal
conscious state and normal vital signs, special attention
should be given to obtaining a history of recently admin-
istered medications. Therefore, clinicians should
recognize adverse reactions to drugs based on a thor-
ough patient history and examination and report such
cases.
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Fig. 2 Chemical structure of Coartem. Artemether has the empirical formula of C16H26O5 (a). C46H58Cl3NO6 for Lumefantrine (b)
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